Last edition
News about "neoadjuvant treatment"
Roche Canada Completes pCPA Negotiations for Perjeta in Early HER2-Positive Breast Cancer
Roche Canada has completed pCPA negotiations for Perjeta in combination with trastuzumab and chemotherapy for eligible patients with HER2-positive early-stage breast cancer, bringing the treatment closer to potential public reimbursement across Canada.
Neoadjuvant Treatment | 20/08/2026 | By News Bureau
Innovent TABOSUN Becomes China's First Approved Domestic Anti CTLA 4 Antibody
Innovent Biologics has received approval from China’s National Medical Products Administration (NMPA) for TABOSUN (Ipilimumab N01 Injection), marking the country’s first domestically developed anti-CTLA-4 monoclonal antibody and a significant milestone in China’s immuno-oncology landscape.
Neoadjuvant Treatment | 26/12/2025 | By News Bureau | 470
EU Approves KEYTRUDA for PD-L1+ Resectable Head and Neck Cancer
KEYTRUDA monotherapy has been approved for use as a neoadjuvant treatment, followed by adjuvant therapy in combination with radiotherapy with or without cisplatin, and continued thereafter as maintenance monotherapy.
Neoadjuvant Treatment | 30/10/2025 | By Dineshwori | 255
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy